27926483|t|The metastasis suppressor CD82/KAI1 inhibits fibronectin adhesion - induced epithelial-to-mesenchymal transition in prostate cancer cells by repressing the associated integrin signaling
27926483|a|The transmembrane protein CD82/KAI1 suppresses the metastatic potential of various cancer cell types. Moreover, decrease or loss of CD82 expression is closely associated with malignancy and poor prognosis in many human cancers including prostate cancer. Despite intense scrutiny, the mechanisms underlying the metastasis - suppressing role of CD82 are still not fully understood. Here, we found that a fibronectin matrix induced mesenchymal phenotypes in human prostate cancer cells with no or low CD82 expression levels. However, high CD82 expression rendered prostate cancer cells to have intensified epithelial characteristics upon fibronectin engagement, along with decreased cell motility and invasiveness. The CD82 function of inhibiting fibronectin - induced epithelial-to-mesenchymal transition (EMT) was dependent not only on CD82 interactions with fibronectin - binding α3β1 / α5β1 integrins but also on the integrin-mediated intracellular signaling events. Notably, CD82 attenuated the FAK-Src and ILK pathways downstream of the fibronectin - receptor integrins. Immunofluorescence staining of human prostate cancer tissue specimens illustrated a negative association of CD82 with EMT -related gene expression as well as prostate malignancy. Altogether, these results suggest that CD82 suppresses EMT in prostate cancer cells adhered to the fibronectin matrix by repressing adhesion signaling through lateral interactions with the associated α3β1 and α5β1 integrins, leading to reduced cell migration and invasive capacities.
27926483	4	25	metastasis suppressor	T017	UMLS:C0949486
27926483	26	35	CD82/KAI1	T103	UMLS:C1528437
27926483	45	56	fibronectin	T103	UMLS:C0016055
27926483	57	65	adhesion	T038	UMLS:C0007577
27926483	76	112	epithelial-to-mesenchymal transition	T038	UMLS:C1523298
27926483	116	124	prostate	T017	UMLS:C0033572
27926483	125	137	cancer cells	T017	UMLS:C0334227
27926483	167	185	integrin signaling	T038	UMLS:C1512812
27926483	190	211	transmembrane protein	T103	UMLS:C0021699
27926483	212	221	CD82/KAI1	T103	UMLS:C1528437
27926483	269	280	cancer cell	T017	UMLS:C0334227
27926483	318	322	CD82	T103	UMLS:C1528437
27926483	323	333	expression	T038	UMLS:C1171362
27926483	361	371	malignancy	T038	UMLS:C4282132
27926483	376	390	poor prognosis	T033	UMLS:C0278252
27926483	399	404	human	T204	UMLS:C0086418
27926483	405	412	cancers	T038	UMLS:C0006826
27926483	423	438	prostate cancer	T038	UMLS:C0376358
27926483	496	506	metastasis	T038	UMLS:C4255448
27926483	529	533	CD82	T103	UMLS:C1528437
27926483	588	599	fibronectin	T103	UMLS:C0016055
27926483	600	606	matrix	T017	UMLS:C0015350
27926483	641	646	human	T204	UMLS:C0086418
27926483	647	655	prostate	T017	UMLS:C0033572
27926483	656	668	cancer cells	T017	UMLS:C0334227
27926483	684	688	CD82	T103	UMLS:C1528437
27926483	689	699	expression	T038	UMLS:C1171362
27926483	722	726	CD82	T103	UMLS:C1528437
27926483	727	737	expression	T038	UMLS:C1171362
27926483	747	755	prostate	T017	UMLS:C0033572
27926483	756	768	cancer cells	T017	UMLS:C0334227
27926483	821	832	fibronectin	T103	UMLS:C0016055
27926483	866	879	cell motility	T038	UMLS:C0007608
27926483	902	906	CD82	T103	UMLS:C1528437
27926483	930	941	fibronectin	T103	UMLS:C0016055
27926483	952	988	epithelial-to-mesenchymal transition	T038	UMLS:C1523298
27926483	990	993	EMT	T038	UMLS:C1523298
27926483	1021	1025	CD82	T103	UMLS:C1528437
27926483	1026	1038	interactions	T038	UMLS:C0872079
27926483	1044	1055	fibronectin	T103	UMLS:C0016055
27926483	1058	1065	binding	T038	UMLS:C0033618
27926483	1066	1070	α3β1	T103	UMLS:C0246766
27926483	1073	1087	α5β1 integrins	T103	UMLS:C1138422
27926483	1104	1145	integrin-mediated intracellular signaling	T038	UMLS:C1155451
27926483	1163	1167	CD82	T103	UMLS:C1528437
27926483	1183	1190	FAK-Src	T038	UMLS:C1148560
27926483	1195	1207	ILK pathways	T038	UMLS:C1148560
27926483	1208	1218	downstream	T082	UMLS:C0522506
27926483	1226	1237	fibronectin	T103	UMLS:C0016055
27926483	1240	1258	receptor integrins	T103	UMLS:C0021701
27926483	1260	1278	Immunofluorescence	T058	UMLS:C0079603
27926483	1279	1287	staining	T058	UMLS:C0487602
27926483	1291	1296	human	T204	UMLS:C0086418
27926483	1297	1312	prostate cancer	T038	UMLS:C0376358
27926483	1313	1329	tissue specimens	T017	UMLS:C1292533
27926483	1344	1352	negative	T033	UMLS:C0205160
27926483	1368	1372	CD82	T103	UMLS:C1528437
27926483	1378	1381	EMT	T038	UMLS:C1523298
27926483	1391	1406	gene expression	T038	UMLS:C0017262
27926483	1418	1426	prostate	T017	UMLS:C0033572
27926483	1427	1437	malignancy	T038	UMLS:C4282132
27926483	1478	1482	CD82	T017	UMLS:C0812444
27926483	1494	1497	EMT	T038	UMLS:C1523298
27926483	1501	1509	prostate	T017	UMLS:C0033572
27926483	1510	1522	cancer cells	T017	UMLS:C0334227
27926483	1538	1549	fibronectin	T103	UMLS:C0016055
27926483	1550	1556	matrix	T017	UMLS:C0015350
27926483	1598	1605	lateral	T082	UMLS:C0205093
27926483	1639	1643	α3β1	T103	UMLS:C0246766
27926483	1648	1662	α5β1 integrins	T103	UMLS:C1138422
27926483	1683	1697	cell migration	T038	UMLS:C1622501